| Drug Name |
Tivozanib |
| Drug ID |
BADD_D02600 |
| Description |
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.[L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] |
| Indications and Usage |
Tivozanib is approved in the USA for the treatment of relapsed or refractory renal cell carcinoma in adult patients who have undergone two or more systemic therapies.[L32524] In the UK and other countries, is indicated as first line therapy of adults with advanced renal cell carcinoma (RCC) and VEGFR and mTOR pathway inhibitor-naïve patients after disease progression following one previous treatment with cytokine therapy for advanced disease.[L17180] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EK03 |
| DrugBank ID |
DB11800
|
| KEGG ID |
D09683
|
| MeSH ID |
C553176
|
| PubChem ID |
9911830
|
| TTD Drug ID |
D0W7JZ
|
| NDC Product Code |
45629-134; 11014-0470; 45629-089; 11014-0457; 11014-0458; 11014-0471 |
| UNII |
172030934T
|
| Synonyms |
tivozanib | AV 951 | AV951 cpd | AV-951 | fotivda | KRN 951 | KRN951 | KRN-951 |
